text_1: Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.
text_2: We now find, in a mouse model of EOC, that clinically relevant doses of DNA methyltransferase and histone deacetylase inhibitors (DNMTi and HDACi, respectively) reduce the immune suppressive microenvironment through type I IFN signaling and improve response to immune checkpoint therapy.